Clinical study of bortezomib in combination with dexamethasone for the treatment of multiple myeloma.
- Author:
Li-Xia WANG
1
;
Hua LU
;
Wen-Yi SHEN
;
Si-Xuan QIAN
;
Hong-Xia QIU
;
Han-Xin WU
;
Jian-Fu ZHANG
;
Yu-Jie WU
;
Jian-Yong LI
Author Information
1. Department of Hematology, The First Hospital, Nanjing Medical University, Nanjing 210029, Jiangsu Province, China.
- Publication Type:Clinical Trial
- MeSH:
Adult;
Aged;
Antineoplastic Agents;
administration & dosage;
Antineoplastic Combined Chemotherapy Protocols;
therapeutic use;
Boronic Acids;
administration & dosage;
Bortezomib;
Dexamethasone;
administration & dosage;
Female;
Humans;
Male;
Middle Aged;
Multiple Myeloma;
drug therapy;
Protease Inhibitors;
administration & dosage;
Pyrazines;
administration & dosage
- From:
Journal of Experimental Hematology
2008;16(4):943-945
- CountryChina
- Language:Chinese
-
Abstract:
The objective of study was to evaluate the efficiency and safety of bortezomib for the treatment of multiple myeloma. Bortezomib in combination with dexamethasone was administered as first-line treatment in all 7 newly diagnosed patients with multiple myeloma. The patients with refractory myeloma were treated with bortezomib in combination with dexamethasone or with other traditional agents such as mitoxantrone and thalidomide. The results showed that according to the EMBT criteria, out of 7 patients one achieved complete response (CR), five achived partial response (PR) and one achived minor response (MR). The 3 patients with refractory/relapsed myeloma achieved PR (2/3) and MR (1/3). The overall response rate (CR + PR) was 80%. The most frequent adverse events observed were thrombocytopenia in three patients, diarrhea and peripheral neuropathy in one respectively. In conclusion, bortezomib demonstrates efficiency in the treatment of new-diagnosed and refractory/relapsed multiple myeloma, and the side effects from treatment are acceptable and manageable.
